TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (1985) 79, 430-434

Malaria, cause of ahaptoglobinaemia in Africans

J. F. TRAPE[1], A. FRIBOURG-BLANC[2], M. F. BOSSENO[1], M. LALLEMANT[1], R. ENGLER[3] AND J. MOUCHET[4]

[1]*Laboratory of Parasitology and Medical Entomology, ORSTOM, BP 181, Brazzaville, People's Republic of the Congo;* [2]*Laboratory of Immunology, 5, bd du Montparnasse, 75006, Paris, France;* [3]*Dept. of Biochemistry, U.E.R. Biomedicale des Saints-Pères, 45 rue des Saints-Pères, 75006 Paris, France;* [4]*ORSTOM, Services Scientifiques Centraux, 70-74, route d'Aulnay, 93140 Bondy, France*

Abstract

The lack of serum haptoglobin in Africans has been investigated in the Congo, Central Africa, where HpO prevalence is about 30%. This study shows that it is possible to suppress ahaptoglobinaemia within a few weeks by antimalarial chemoprophylaxis, that it does not occur in protected individuals, that ahaptoglobinaemia reappears at its original incidence levels after interruption of chemoprophylaxis, and that some individuals are more susceptible in relation to Hp^2 gene. Malaria is the only significant cause of ahaptoglobinaemia in subjects both with and without detectable parasitaemia. The possible mechanisms involved are discussed.

Introduction

The cause of the lack of serum haptoglobin in Africans, first reported in Nigerians by ALLISON *et al.* (1958), remains unknown. About 20 to 40% of individuals are ahaptoglobinaemic (HpO) in tropical Africa (ALLISON *et al.*, 1958; BLUMBERG & GENTILE, 1961; GIBLETT *et al.*, 1966; SUTTON, 1970; ROUGET

Methods and Results

From November 1980 to January 1982, 14 successive surveys which included a battery of biological and clinical investigations were made on 250 schoolchildren in Linzolo village, Congo, 25 km south-west of Brazzaville. Plasma samples were collected by finger prick. The Hp level was measured by immunonephelometry. Plasma was diluted

Table II—Percentage of HpO according to malaria parasitaemia (All species; surveys 1, 2, 3 and November 81). Parasitaemia was assessed by a standard examination of 200 fields of stained thick blood film and parasite count in relation to the number of leucocytes on the basis of 8000 per μl of blood. Parasite density classes: 0: no parasite observed; 1: <50/μl; 2: 50-499/μl; 3: 500-4999/μl; 4: 5000/49999/μl; 5: ≥50000/μl. A single parasite observed in 200 fields corresponds to about 2·5 parasites per μl

Parasite density (classes)	Hp present	HpO	% HpO	No.
0	142	36	20·2%	178
1	114	35	23·5%	149
2	132	65	33%	197
3	103	62	37·6%	165
4	73	53	42·1%	126
5	11	4	26·7%	15
Total	575	255	30·7%	830

Table III—Percentage of HpO to *Plasmodium malariae* parasite density (surveys 1, 2, 3 and November 81)

Parasite density (classes)	Hp present	HpO	% HpO	No.
1	28	19	40·4%	47
2	24	19	44·2%	43
3	7	11	61·1%	18
Total	59	49	45·4%	108

Table IV—*Plasmodium malariae* infections: associated *P. falciparum* parasitaemia according to the presence or absence of haptoglobin

	P. falciparum parasite density						
	0	1	2	3	4	5	Total
Hp present	9	4	16	18	12	0	59
HpO	8	2	10	17	12	0	49
Total	17	6	26	35	24	0	108

malariae, despite a generally low parasitaemia, and reached 61·1% in heavy infections with this species (Tables III and IV).

Effect of amodiaquine

After the third survey, weekly antimalarial chemoprophylaxis with amodiaquine (Flavoquine^{R}, 10 mg/kg) was started in 167 schoolchildren for three months (April to June 1981). At the beginning of treatment, 55 schoolchildren (32·9%) were HpO. After six weeks, only four of 164 (2·4%) schoolchildren and after three months, only two of 119 (1·7%) schoolchildren were HpO. All the individuals absent at this last survey were Hp positive at the previous survey.

During chemoprophylaxis, seven additional weekly surveys were made in 54 individuals, of whom 33 were HpO at the beginning of treatment. Haptoglobin appeared in them after a delay of one week to two months and usually in less than one month. However, a transient ahaptoglobinaemia was observed in seven individuals under treatment. Six of these individuals (Table V: subjects Nos. 311, 315, 327 and 353; Table VI: subjects Nos. 251 and 542) were already HpO at the beginning of treatment: after generally appearing rapidly, usually within less than one month, haptoglobin disappeared before reappearing most often at the end of the second month and remaining in three or four successive weekly tests.

17 of the 18 individuals who were constantly HpO in the first three surveys were included in this study. All standardized their haptoglobin level when treated with amodiaquine (Table V).

Results after the interruption of amodiaquine

Chemoprophylaxis was interrupted during five months (July to November 1981). A fresh survey was made in November. 104 of the schoolchildren who had previously had chemoprophylaxis were found. 34 (32·7%) were HpO in April at the beginning of chemoprophylaxis and all had standardized their haptoglobin level when treated. In November, 27 (26%) 16 of which were new individuals were HpO.

This survey also included 126 subjects who had not previously had chemoprophylaxis: 32 subjects (25·4%) were HpO. Among the 126 subjects, 59 had been previously investigated in April and 14 (23·7%) were HpO at that time; in November, 13 subjects (22%) were HpO, but only four of these were the same individuals as in April.

Table V—Evolution of haptoglobin level (mg/100 ml) under weekly antimalarial chemoprophylaxis with amodiaquine in 17 schoolchildren who were constantly HpO in the first three surveys

Patient	Days									
	0	8	15	25	40	49	61	69	75	82
217	0	—	—	—	35	—	—	—	—	—
248	0	55	—	145	110	210	200	200	145	130
311	0	0	100	—	0	0	45	185	55	50
315	0	0	110	0	45	275	60	185	110	145
327	0	0	25	0	0	0	40	60	65	75
343	0	—	—	35	45	100	75	120	50	—
346	0	—	—	—	100	—	125	265	145	—
353	0	—	—	10	20	0	40	55	45	—
365	0	—	—	—	—	—	40	65	—	—
372	0	—	—	—	130	—	125	310	130	110
375	0	—	—	—	65	—	110	175	165	220
381	0	30	120	110	110	185	190	310	120	—
385	0	—	—	—	145	—	175	330	—	—
388	0	0	—	—	65	90	155	155	130	165
390	0	—	—	—	45	—	55	80	55	75
391	0	0	—	—	35	65	90	175	130	145
405	0	—	—	—	0	—	120	—	—	100

Table VI—Evolution of haptoglobin level (mg/100 ml) under weekly antimalarial chemoprophylaxis with amodiaquine in 16 schoolchildren who were HpO at the beginning of the treatment

Subject	Days									
	0	8	15	25	40	49	61	69	75	82
251	0	—	—	—	145	0	200	155	90	100
267	0	55	110	105	50	50	175	200	145	130
277	0	25	—	90	110	115	120	145	45	—
278	0	65	175	210	105	185	190	275	110	50
291	0	—	—	120	130	—	130	—	—	120
301	0	0	130	80	95	100	90	155	145	110
309	0	—	—	—	65	—	120	—	90	275
319	0	0	90	—	50	110	175	275	130	120
330	0	0	80	145	165	295	145	155	75	45
333	0	90	100	135	100	130	330	250	175	275
339	0	55	—	130	90	155	165	240	110	—
348	0	—	165	—	120	—	—	250	165	—
407	0	65	145	110	90	115	145	175	110	100
412	0	—	—	50	55	—	145	240	110	265
508	0	—	—	—	90	—	120	—	100	25
542	0	—	—	—	25	—	45	65	35	0

Table VII—Distribution of haptoglobin types in (A) 32 individuals who had never been HpO in four samples taken in the absence of chemoprophylaxis and (B) 18 individuals who have been at least three times HpO in

Group	No.	Phenotype			Hp^2 frequency
		1-1	2-1	2-2	
A	32	14	17	1	0·30
B	18	2	13	3	0·53

Table VIII—Distribution of HbAS individuals according to the number of times HpO was observed in the same individual in the course of three surveys made at intervals of two months

HpO	0	1	2	3	Total
No. of individuals (Total)	73	43	29	18	163
No. of individuals with HbAS	20 (27·4%)	6 (13·9%)	6 (20·7%)	9 (50%)	41 (25·2%)

Comparison of amodiaquine and mefloquine

The 174 schoolchildren were randomly divided into two groups. One group of 89 was treated weekly with amodiaquine as previously, and the other (85) with a monthly dose of mefloquine (20 mg/kg up to 25 kg, 500 mg from 25 to 40 kg, 625 mg above 40 kg). After two months (January 1982), another survey was done on both groups. Of the 89 individuals treated with amodiaquine, none was HpO, compared with 29 (32·6%) who had been HpO at the beginning of treatment. Of the 85 individuals treated with mefloquine, only one was HpO (1·2%), whereas 22 (25·9%) had been HpO at the beginning of treatment.

Correlations with haptoglobin phenotype

The haptoglobin phenotype was determined by the polyacrylamide gradient gel method (ENGLER *et al.*, 1973) in (a) 32 individuals who had never been HpO in the four samples taken in the absence of chemoprophylaxis and (b) 18 individuals who were HpO at least three times in the same four samples. The three common phenotypes were observed in the two groups of individuals (Table VII). However the Hp^2 gene frequency was significantly higher ($P<0·05$) in those individuals who were regularly HpO.

Correlations with sickle cell trait

Sickle cell trait (HbAS) was observed in 41 of the 163 schoolchildren present in the first three surveys.

To investigate if individuals with HbAS were more frequently HpO than others, we studied their distribution according to the number of times HpO occurred in the same individual in the three surveys.

Results are given in Table VIII. There appears to be no relation between sickle cell trait and HpO. However, 9 of the 18 individuals constantly HpO in these three surveys are HbAS subjects.

Discussion

Our results show that it is possible to eliminate ahaptoglobinaemia in a population in tropical Africa through antimalarial chemoprophylaxis. Of the 237 schoolchildren studied while receiving chemoprophylaxis, not one remained constantly HpO. The existence of a null allele Hp^0, which has been proposed for a long time to explain the high frequency of HpO in Africans, can be excluded in this population. Potential causes of ahaptoglobinaemia other than malaria,

whether genetic or acquired, can be excluded as significant causes and their frequency is no higher than that observed in the non-African populations.

How does malaria act? The function of haptoglobin is to bind free haemoglobin. It is probable that when infected erythrocytes are haemolysed, both by direct damage by invasion and growth of the parasites and by sequestration of parasitized cells in the spleen and other parts of the micro-circulation, haemoglobin is liberated and swiftly complexed with haptoglobin, thus initiating a fall in Hp level correlated with the severity of the parasitaemia. However, HpO was frequently observed in individuals with negative thick

ahaptoglobinaemia once parasitaemia has disappeared. However, this seems to be very unlikely since an increase of haptoglobin synthesis is observed in any inflammatory syndrome which is not associated with liver alterations (ENGLER & JAYLE, 1976). A significant increase of the mean level of α_1 glycoprotein (orosomucoïd) was observed in HpO individuals, which paradoxically suggests an increase in haptoglobin synthesis. This would constitute a mechanism which opposes ahaptoglobinaemia.

The hypothesis which would account best for our observations is that of the existence in HpO individuals of a high rate immune haemolysis induced by

populations, although repeated recent attempts to demonstrate it were largely unsuccessful.

References

Abdalla, S. & Weatherall, D. J. (1982). The direct antiglobulin test in *P. falciparum* malaria. *British Journal of Haematology*, **51**, 415-425.

Abdalla, S., Weatherall, D. J., Wickramasinghe, S. N. & Hughes, M. (1980). The anaemia of *P. falciparum* malaria. *British Journal of Haematology*, **46**, 171-183.

Allison, A. C. (1959). Genetic control of human haptoglo-

other African populations. *American Journal of Human Genetics*, **18**, 553-558.

Giblett, E. R. & Steinberg, A. G. (1960). The inheritance of serum haptoglobin types in American Negroes: Evidence for a third allele Hp^{2m}. *American Journal of Human Genetics*, **12**, 160-169.

Lefevre-Witier, P. (1974). Un "Isolat" du Sud Sahara: les Kel Kummer. VI. Structure génétique des systèmes sanguins erythrocytaires et sériques. *Population*, **29**, 517-527.

Monjour, L., Trape, J. F., Druilhe, P., Bourdillon, F.,